EyePoint, Inc. (EYPT)
NASDAQ: EYPT · Real-Time Price · USD
13.58
+0.08 (0.59%)
At close: May 29, 2026, 4:00 PM EDT
13.30
-0.28 (-2.06%)
After-hours: May 29, 2026, 7:56 PM EDT
EyePoint Employees
EyePoint had 214 employees as of December 31, 2025. The number of employees increased by 49 or 29.70% compared to the previous year.
Employees
214
Change (1Y)
49
Growth (1Y)
29.70%
Revenue / Employee
$35,579
Profits / Employee
-$1,269,154
Market Cap
1.14B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 214 | 49 | 29.70% | 214 | 0 |
| Dec 31, 2024 | 165 | 44 | 36.36% | 165 | 0 |
| Dec 31, 2023 | 121 | -23 | -15.97% | 121 | 0 |
| Dec 31, 2022 | 144 | 21 | 17.07% | 144 | 0 |
| Dec 31, 2021 | 123 | 22 | 21.78% | 122 | 1 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| MannKind | 592 |
| Maravai LifeSciences Holdings | 416 |
| Zenas BioPharma | 167 |
| DBV Technologies | 161 |
| Absci | 140 |
| Olema Pharmaceuticals | 137 |
| Inventiva | 77 |
| Jade Biosciences | 55 |
EYPT News
- 5 days ago - EyePoint Pharmaceuticals Eyes Transformative 2026 as DURAVYU Phase 3 Data Nears - MarketBeat
- 5 days ago - EyePoint Transcript: Stifel 2026 Virtual Ophthalmology Forum - Transcripts
- 12 days ago - EyePoint Announces Participation at Upcoming Investor Conferences - GlobeNewsWire
- 13 days ago - EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewsWire
- 17 days ago - EyePoint receives positive DSMC recommendation for Duravyu Phase 3 trials - TheFly
- 17 days ago - EyePoint's late-stage eye drug trials to continue after safety panel review - Reuters
- 17 days ago - EyePoint Announces Third Consecutive Positive DSMC Recommendation for Phase 3 Wet AMD Trials for DURAVYU™, Building Confidence Ahead of Mid-2026 Topline Data - GlobeNewsWire
- 24 days ago - EyePoint reports Q1 EPS (99c), consensus (81c) - TheFly